eRapa™ was originally developed for use in aging studies at the Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, and it is the only pharmaceutical agent tested thus far to demonstrate significantly increased health span and lifespan in rodent models.
Developed by Z. David Sharp and Randy Strong at UT Health San Antonio and licensed for development to RHI in 2012, the eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer (Eudragit® L 100 / S 100). This improved formulation and better bio-availability enables eRapa to consistently provide approximately 30% more drug than sirolimus (RHI unpublished data). eRapa’s improved and predictable delivery allows for consistent and sustained lower dosing, which is anticipated to result in an improved toxicity profile since rapamycin’s toxicity is related to blood concentration levels.
Research studies show chronic, intermittent, low-dose rapamycin:
- Augments the immune system.
- Prevents cancer in cancer-prone animals and also prolongs health span and life span.
- Reduces the percentage of CD4 and CD8 T lymphocytes that express PD-1 (exhaustion marker), which inhibits T cell signaling and is more highly expressed with age and exposure to cancer.
- Prostate Cancer: Recent results suggest that targeting mTORC1 and/or inflammation signaling may be an effective strategy for reducing prostate cancer and prostate specific mortality.1
- Familial Adenomatous Polyposis (colon cancer precursor): eRapa dosed mice showed minimal disease development, and even exceeded the expected life span of normal non-engineered mice with some living beyond day 1,000 of the study.2
- Similar results have also been found in bladder, breast and lung cancers.
- Mays Cancer Center at UT Health San Antonio
- Dr. Ian Thompson, Jr. and Dr. Mike Liss
- eRapa patent and licenses cover composition of matter and manufacturing process for an immuno-oncology drug that stimulates the body’s immune system to prevent the progression and recurrence of cancer.
1 Effect of Metformin, Rapamycin, and Their combination on Growth and Progression Of prostate tumors in HiMyc Mice, DiGiovani, et al, 2015
2 eRapa Restores A Normal Life Span in a FAP Mouse Model, Hasty, et. al. Nov 26th, 2013